U.S. patent approval for Intervacc’s vaccine against infections caused by Streptococcus suis
Stockholm, November 22, 2023 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine against Streptococcus suis infections in pigs. The U.S. Patent No. 11,814,415 relates to a vaccine based on recombinant fusion proteins where patent protection is effective until 2037.
Streptococcus suis (S. suis) is an endemic cause of disease that results in significant economic losses to the pig industry throughout the world. The bacterium is transmitted from sows to piglets